In any significant corporate governance controversy, the de facto “deciders” are the largest institutional investors. This new balance of power sets the policy and research agenda. The Institute for Corporate Governance and Finance was launched in 2016 to address these issues, taking advantage of the concentration of finance, talent, and activity in New York and at New York University. Whatever the issue—activist shareholders, short-term versus long-term investment horizons, compensation, control contests, going private, spinoffs, etc.—the central questions should be “what do the big institutions think?” and “what should the big institutions think?” The institute brings key people together to understand these questions and encourage the development of institutional investors as a responsible force in corporate governance.
To read more about our Launch Event, please click here.
“The Fit between Activists and Mainstream Investors”
April 28, 2017 (By Invitation Only)
What is the role of poison pills in corporate governance today?
Professors Marcel Kahan and Edward Rock, “Anti-Activist Poison Pills”
Commentators: Stephen Fraidin, Pershing Square; Jeffrey Gordon, Columbia Law School
Should institutional investors rethink their opposition to “clear day” poison pills?
Professor Emiliano Catan LLM '10, “The Insignificance of Clear Day Poison Pills”
Commentators: Patrick McGurn, Institutional Shareholder Services; Roberta Romano, Yale Law School
What is the difference in the roles of activist and mainstream investors?
Panel: Glenn Booream, Vanguard; Michelle Edkins, BlackRock; Rakhi Kumar, State Street; Jim Rossman, Lazard; Brian Schorr '82, Trian Partners; Chancellor Andre Bouchard, Delaware Chancery Court; Kevin McCarthy, BNY Mellon; and David Katz '88, Wachtell, Lipton, Rosen & Katz